NCT07128316

LASIK Using Contoura With Phorcides vs. iDesign

Comparison of Clinical Outcomes of LASIK Using Contoura With Phorcides vs. iDesign

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 63 (estimated)
• Sponsor: 59th Medical Wing · Federal
• Sex: All
• Age: 21 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Participants will undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia.

Detailed description

Once consented to participate in the study, subjects will have a comprehensive ocular examination to determine eligibility to undergo LASIK using Contoura with Phorcides calculation on one eye and LASIK using iDesign calculation on the contralateral eye to correct myopia. The study objective is to compare the 6-month visual outcomes (i.e., visual acuity, contract sensitivity, high order aberrations), quality of vision (i.e., double vision, glare, starburst, halos, etc.) and dry eye symptoms of patients undergoing contralateral LASIK using Contoura with Phorcides calculation vs. LASIK using iDesign calculation. Surgical treatment will be randomized so there is a 50% chance to receive LASIK using Contoura with Phorcides vs LASIK using iDesign calculation on the contralateral eye. Subjects will receive standard of care topical ophthalmic antibiotic and steroid drops. This will be a prospective randomized double blind contralateral study. The patient and the staff doing the post-op evaluations will be blinded to which eye received which treatment.

Conditions

• Myopia
• Astigmatism

Interventions

Type	Name	Description
DEVICE	Contoura Topolyzer with Phorcides	LASIK calculated ablation using Contoura Topolyzer with Phorcides
DEVICE	iDesign	LASIK calculated ablation using iDesign Refractive Studio 2.0

Timeline

• Start date: 2023-09-11
• Primary completion: 2025-12-15
• Completion: 2025-12-15
• First posted: 2025-08-18
• Last updated: 2025-08-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study